Article
Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance.
Anticancer research - 1 May 2026
Nakatani Haruka, Kawachi Hayato, Yamada Tadaaki, Furuya Naoki, Tanaka Hisashi, Yoshimura Akihiro, Oba Tomohiro, Hibino Makoto, Fukuda Takahito, Goto Yasuhiro, Nakao Akira, Ogusu Shinsuke, Okazaki Yuta, Harada Taishi, Ota Takayo, Masubuchi Ken, Mikami Koji, Hata Tae, Morimoto Kenji, Takayama Koichi
Abstract excerpt
BACKGROUND/AIM: Cancer cachexia, characterized by weight loss and systemic inflammation, has been associated with poor prognosis in non-small cell lung cancer (NSCLC). However, its impact on treatment outcomes in tumors with mutant epidermal growth factor receptor (EGFR) remains unclear. This multicenter retrospective cohort study evaluated the impact of cancer cachexia on treatment selection after the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.